Survodutide
Stronger clinical signalAlso known as: BI 456906 · glucagon/GLP-1 dual agonist
A Boehringer Ingelheim glucagon-receptor/GLP-1-receptor dual agonist in late-stage development for obesity and MASH (fatty liver disease). Part of the current wave of multi-receptor peptides competing with tirzepatide and retatrutide for the metabolic-peptide spotlight.
Mechanism (plain language)
Engages both the glucagon receptor and the GLP-1 receptor. The glucagon component is proposed to add hepatic lipid metabolism and energy-expenditure effects on top of GLP-1's appetite and glycemic effects.
What research suggests
A phase 2 dose-finding trial in adults with obesity reported dose-dependent weight loss (up to roughly 15% at the highest dose over 46 weeks versus placebo). A subsequent phase 3 trial (SYNCHRONIZE-1) reported significantly greater weight reduction than placebo at 76 weeks.
Uncertainties & risks
Still investigational as of last review; not an approved consumer product. Gastrointestinal adverse events are the most common side effect across trials. Comparative long-term safety versus approved incretin therapies is not yet established.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
2024 · human
Dose-dependent weight loss up to ~14.9% at 46 weeks with the highest dose versus placebo.
- Survodutide Once Weekly for the Treatment of Adults with Obesity
2026 · human
Phase 3 SYNCHRONIZE-1 trial: significantly greater body-weight reduction than placebo at 76 weeks.